MARKET

VNDA

VNDA

Vanda Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.67
-0.11
-0.66%
After Hours: 15.19 -1.48 -8.88% 18:59 04/16 EDT
OPEN
16.83
PREV CLOSE
16.78
HIGH
16.99
LOW
16.29
VOLUME
266.18K
TURNOVER
--
52 WEEK HIGH
20.51
52 WEEK LOW
9.00
MARKET CAP
914.89M
P/E (TTM)
39.49
1D
5D
1M
3M
1Y
5Y
Diabetic Gastroparesis Treatment Market to Continue Impressive Measured Growth through 2027
Apr 15, 2021 (Market Insight Reports) -- Diabetic gastroparesis is delayed gastric emptying associated with diabetes. The condition occurs in patients...
Market Insight Reports · 2d ago
Insomnia Medication Market 2021 Analysis by Key Players, End-User, Type, Application, Regions and Forecast to 2027
Apr 14, 2021 (Market Insight Reports) -- The latest report as Insomnia Medication Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Insight Reports · 3d ago
With Sales Expected To Rise, Vanda Pharmaceuticals Stock Could Surge
Vanda Pharmaceuticals Inc. (VNDA) is a US biopharma marketer and developer of treatments intended to address specific unmet medical needs. Currently, even stronger demand is expected for the company’s products, with the total addressable market for its fla...
TipRanks · 04/06 11:40
Global Pipeline Analysis Market Outlook, Industry Analysis and Prospect 2020
Heraldkeepers · 04/05 11:14
Global Insomnia Therapy Market 2020 Product Introduction, Recent Developments, Competitive Landscape and Dynamics by 2025
Mar 30, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has published a report titled Global Insomnia Therapy Market Growth (Status and Outlook)...
CDN Newswire · 03/30 21:45
Global Insomnia Drugs Market Trends , Report Explores Key Regions, Top Leading Countries, Companies, Consumption, Drivers, Forces Analysis, Revenue, Opportunity and Challenge 2021 to 2025
Mar 25, 2021 (The Expresswire) -- Global "Insomnia Drugs Market" (2021-2025) research provides key analysis on the market status of the Insomnia Drugs...
The Express Wire · 03/25 06:47
Vanda Pharmaceuticals Stock Appears To Be Modestly Undervalued
GuruFocus News · 03/24 21:33
Insomnia Medication Market Analysis, Size, Share, Trends and Forecast 2020-2027 |Ameco Research
pune, India, Wed, 24 Mar 2021 07:37:08 / Comserve Inc. / -- Insomnia Medication Market 2020: This report provides a basic overview of the industry, including...
Comserve · 03/24 14:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VNDA. Analyze the recent business situations of Vanda Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VNDA stock price target is 24.00 with a high estimate of 24.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 259
Institutional Holdings: 68.71M
% Owned: 125.20%
Shares Outstanding: 54.88M
TypeInstitutionsShares
Increased
59
3.09M
New
28
1.68M
Decreased
63
3.45M
Sold Out
15
637.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Director
H. Thomas Watkins
Chief Executive Officer/President/Director
Mihael Polymeropoulos
Chief Financial Officer/Vice President/Treasurer
Kevin Moran
Senior Vice President/Chief Compliance Officer
Gian Piero Reverberi
Senior Vice President/Chief Compliance Officer
Gianpiero Reverberi
Senior Vice President/Chief Marketing Officer
Joakim Wijkstrom
Senior Vice President/General Counsel/Secretary
Timothy Williams
Senior Vice President
Gunther Birznieks
Other/IR Contact Officer
Aranthan Jones
Independent Director
Phaedra Chrousos
Independent Director
Richard Dugan
Independent Director
Stephen Mitchell
Independent Director
Anne Ward
No Data
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Webull offers kinds of Vanda Pharmaceuticals Inc. stock information, including NASDAQ:VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.